Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP

Next Previous
X
Search
Trial Profile

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Stenoparib (Primary)
  • Indications Carcinoma; Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PREDICT 2X-121
  • Sponsors Allarity Therapeutics

    • Most Recent Events

    • 06 Feb 2025 According to an Allarity Therapeutics media release, the company announced that with the new phase 2 protocol, it will capitalize and expand on the ongoing phase 2 clinical trial data to optimize the dose of stenoparib and to refine the DRP patient selection criteria in order to maximize the clinical benefit from stenoparib.
    • 06 Feb 2025 According to an Allarity Therapeutics media release, the company announced that patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities. Recruitment will commence at leading U.S. trial sites, with the potential inclusion of additional sites in the U.K. as warranted.
    • 23 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top